Advanced Proteome Therapeutics Corporation

BST:0E81 Stock Report

Market Cap: €140.0k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Advanced Proteome Therapeutics Past Earnings Performance

Past criteria checks 0/6

Advanced Proteome Therapeutics's earnings have been declining at an average annual rate of -5.7%, while the Biotechs industry saw earnings growing at 16.9% annually.

Key information

-5.7%

Earnings growth rate

12.7%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Apr 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Advanced Proteome Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:0E81 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Apr 230-201
31 Jan 230-101
31 Oct 220001
31 Jul 220101
30 Apr 220101
31 Jan 220001
31 Oct 210-101
31 Jul 210-200
30 Apr 210-210
31 Jan 210-110
31 Oct 200-110
31 Jul 200010
30 Apr 200010
31 Jan 200010
31 Oct 190010
31 Jul 190010
30 Apr 190010
31 Jan 190010
31 Oct 180-110
31 Jul 180-110
30 Apr 180010
31 Jan 180-110
31 Oct 170-110
31 Jul 170-110
30 Apr 170-110
31 Jan 170-110
31 Oct 160-110
31 Jul 160-110
30 Apr 160-110
31 Jan 160-110
31 Oct 150-110
31 Jul 150-110
30 Apr 150010
31 Jan 150010
31 Oct 140-110
31 Jul 140-110
30 Apr 140-210
31 Jan 140-210
31 Oct 130-110
31 Jul 130-110

Quality Earnings: 0E81 is currently unprofitable.

Growing Profit Margin: 0E81 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0E81 is unprofitable, and losses have increased over the past 5 years at a rate of 5.7% per year.

Accelerating Growth: Unable to compare 0E81's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0E81 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).


Return on Equity

High ROE: 0E81's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies